Part 2 of the Bloomberg Law article on government scrutiny of the relationship between manufacturers and specialty pharma
The manufacturer/specialty pharmacy relationship and attendant risks should be on the agenda of every compliance officer in the life sciences industry. Specialty pharmacies are uniquely positioned to connect manufacturers, prescribers, and patients. In Part I of this two-part series, Bllomberg Law covered the wide-ranging role of specialty pharmacies in the dispensing of specialty drugs, and the increased risks of government scrutiny and enforcement around them. These risks warrant a tailored compliance program directed at specialty pharmacy activities, as we will cover in Part II of this series.
This article features REGINA GORE CAVALIERE and EVAN BARTELL.